Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H53N3O6 |
Molecular Weight | 551.7583 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC
InChI
InChIKey=UXOWGYHJODZGMF-QORCZRPOSA-N
InChI=1S/C30H53N3O6/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35)/t22-,23-,24-,25-/m0/s1
Aliskiren – the only direct renin inhibitor which is clinically used as an antihypertensive drug. Aliskiren is the first of a new class of antihypertensive agents. Aliskiren is a new renin inhibitor of a novel structural class that has recently been shown to be efficacious in hypertensive patients after once-daily oral dosing. In short-term studies, it was effective in lowering blood pressure either alone or in combination with valsartan and hydrochlorothiazide, and had a low incidence of serious adverse effects. It was approved by the Food and Drug Administration in 2007 for the use as a monotherapy or in combination with other antihypertensives. Aliskiren is marketed under the trade name Tekturna. Aliskiren effectively reduces functional plasma renin activity by binding to renin with high affinity, preventing it from converting angiotensinogen to angiotensin I. The inhibition of renin by aliskiren is associated with a reduction in circulating levels of angiotensin I and II, with a resultant increase in plasma renin concentration and inhibit activation of mitogen-activated protein kinases ERK1 (p44) and ERK2 (p42).
Originator
Sources: http://adisinsight.springer.com/drugs/800010738 | https://www.ncbi.nlm.nih.gov/pubmed/21687346
Curator's Comment: # Novartis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL286 |
0.6 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TEKTURNA Approved UseAmturnide is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Amturnide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed combination drug is not indicated for initial therapy of hypertension. Amturnide is a combination of aliskiren, a renin inhibitor, amlodipine besylate, a dihydropyridine calcium channel blocker, and hydrochlorothiazide (HCTZ), a thiazide diuretic. Amturnide is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions: Not indicated for initial therapy. (1) Launch Date2007 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
290.2 ng/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALISKIREN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
102 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fed |
|
108 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fed |
|
252 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fasted |
|
273 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fasted |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1399 ng × h/mL |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALISKIREN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
1100 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fed |
|
1540 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fasted |
|
1580 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fasted |
|
872 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01570686 |
300 mg 1 times / day steady, oral dose: 300 mg route of administration: oral experiment type: steady co-administered: |
ALISKIREN plasma | Homo sapiens population: unhealthy age: sex: food status: Fed |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41 h |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ALISKIREN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg single, oral Highest studied dose |
healthy, 18 - 45 n = 8 Health Status: healthy Age Group: 18 - 45 Sex: M+F Population Size: 8 Sources: |
|
600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: Page: p.1161 |
unhealthy, 53 n = 166 Health Status: unhealthy Condition: Hypertension Age Group: 53 Sex: M+F Population Size: 166 Sources: Page: p.1161 |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (0.6%) Sources: Page: p.1161 |
300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hypertension Sources: Page: p.1 |
Disc. AE: Disorder fetal, Angioedema... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: Page: p.1Angioedema Angioedema Hypotension Impaired renal function Hyperkalemia |
150 mg 1 times / day steady, oral Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: |
unhealthy n = 7 Health Status: unhealthy Condition: Kidney Transplant Population Size: 7 Sources: |
Other AEs: GI bleed, Knee hemarthrosis... Other AEs: GI bleed (serious, 1 patient) Sources: Knee hemarthrosis (serious, 1 patient) Diarrhea (below serious, 5 patients) Lower extremities weakness of (below serious, 1 patient) |
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Other AEs: Cellulitis, Pneumonia... Other AEs: Cellulitis (serious, 1 patient) Sources: Pneumonia (serious, 1 patient) Diabetic foot (serious, 1 patient) Choroidal neovascularisation (below serious, 1 patient) Foreign body sensation in eyes (below serious, 1 patient) Asteroid hyalosis (below serious, 1 patient) Retinal neovascularisation (below serious, 1 patient) Vision blurred (below serious, 1 patient) Vitreous detachment (below serious, 1 patient) Diarrhoea (below serious, 1 patient) Flatulence (below serious, 1 patient) Fatigue (below serious, 1 patient) Fungal skin infection (below serious, 1 patient) Respiratory tract infection (below serious, 1 patient) Sinusitis (below serious, 1 patient) Tooth fracture (below serious, 1 patient) Hypoglycaemia (below serious, 1 patient) Arthritis (below serious, 1 patient) Muscle spasms (below serious, 1 patient) Myalgia (below serious, 1 patient) Pain in extremity (below serious, 1 patient) Pain in jaw (below serious, 1 patient) Basal cell carcinoma (below serious, 2 patients) Paraesthesia (below serious, 1 patient) Epistaxis (below serious, 1 patient) Hypotension (below serious, 2 patients) |
300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Other AEs: Anaemia, Haemorrhagic disorder... Other AEs: Anaemia (serious, 6 patients) Sources: Haemorrhagic disorder (serious, 1 patient) Hilar lymphadenopathy (serious, 1 patient) Lymphadenopathy (serious, 1 patient) Splenic infarction (serious, 1 patient) Angina unstable (serious, 7 patients) Aortic valve incompetence (serious, 1 patient) Arteriospasm coronary (serious, 1 patient) Atrial flutter (serious, 3 patients) Atrioventricular block complete (serious, 2 patients) Cardio-respiratory arrest (serious, 7 patients) Cardiogenic shock (serious, 7 patients) Cardiomyopathy (serious, 1 patient) Cardiopulmonary failure (serious, 2 patients) Coronary artery disease (serious, 4 patients) Left ventricular dysfunction (serious, 1 patient) Low cardiac output syndrome (serious, 1 patient) Fibrosis myocardial (serious, 1 patient) Tachyarrhythmia (serious, 1 patient) Tachycardia (serious, 3 patients) Ventricular extrasystoles (serious, 1 patient) Ventricular tachycardia (serious, 10 patients) Vertigo (serious, 4 patients) Cataract (serious, 3 patients) Retinal detachment (serious, 1 patient) Constipation (serious, 2 patients) Duodenal ulcer haemorrhage (serious, 1 patient) Enterocolitis (serious, 1 patient) Gastritis (serious, 1 patient) Hiatus hernia (serious, 1 patient) Intestinal obstruction (serious, 1 patient) Intestinal polyp (serious, 1 patient) Nausea (serious, 8 patients) Small intestinal obstruction (serious, 1 patient) Umbilical hernia, obstructive (serious, 1 patient) Upper gastrointestinal haemorrhage (serious, 1 patient) Vomiting (serious, 5 patients) Chest discomfort (serious, 1 patient) Chest pain (serious, 6 patients) Device lead issue (serious, 1 patient) Drug intolerance (serious, 1 patient) Necrosis (serious, 1 patient) Non-cardiac chest pain (serious, 7 patients) Soft tissue inflammation (serious, 1 patient) Sudden death (serious, 9 patients) Cholecystitis (serious, 2 patients) Hepatic cirrhosis (serious, 1 patient) Hepatic cyst (serious, 1 patient) Hepatorenal syndrome (serious, 1 patient) Heart transplant rejection (serious, 1 patient) Anal abscess (serious, 1 patient) Appendicitis (serious, 2 patients) Bronchitis bacterial (serious, 1 patient) Erysipelas (serious, 2 patients) Gastrointestinal viral infection (serious, 1 patient) Hepatitis B (serious, 1 patient) Liver abscess (serious, 1 patient) Infection localised (serious, 1 patient) Lower respiratory tract infection (serious, 3 patients) Orchitis (serious, 1 patient) Osteomyelitis acute (serious, 1 patient) Paronychia (serious, 1 patient) Pseudomembranous colitis (serious, 2 patients) Respiratory tract infection (serious, 3 patients) Sepsis (serious, 8 patients) Viral infection (serious, 1 patient) Wound infection pseudomonas (serious, 1 patient) Accidental overdose (serious, 1 patient) Ankle fracture (serious, 1 patient) Contusion (serious, 1 patient) Dermatitis artefacta (serious, 1 patient) Electric shock (serious, 1 patient) Extradural haematoma (serious, 1 patient) Femoral neck fracture (serious, 1 patient) Femur fracture (serious, 4 patients) Head injury (serious, 1 patient) Humerus fracture (serious, 2 patients) Laceration (serious, 1 patient) Post procedural haematoma (serious, 1 patient) Procedural haemorrhage (serious, 1 patient) Pubis fracture (serious, 1 patient) Spinal compression fracture (serious, 1 patient) Splenic rupture (serious, 1 patient) Subdural haematoma (serious, 2 patients) Thermal burn (serious, 1 patient) Toxicity to various agents (serious, 2 patients) Blood creatinine increased (serious, 3 patients) Haemoglobin decreased (serious, 1 patient) International normalised ratio increased (serious, 2 patients) Renal function test abnormal (serious, 1 patient) Decreased appetite (serious, 1 patient) Diabetic ketoacidosis (serious, 1 patient) Failure to thrive (serious, 1 patient) Fluid intake reduced (serious, 1 patient) Hypoglycaemia (serious, 7 patients) Arthralgia (serious, 1 patient) Arthritis (serious, 1 patient) Bursitis (serious, 1 patient) Costochondritis (serious, 1 patient) Joint effusion (serious, 1 patient) Muscular weakness (serious, 1 patient) Pain in extremity (serious, 2 patients) Bladder neoplasm (serious, 1 patient) Colon cancer (serious, 2 patients) Colorectal cancer (serious, 1 patient) Hepatic neoplasm (serious, 1 patient) Hepatobiliary neoplasm (serious, 1 patient) Adenocarcinoma lung (serious, 1 patient) Lung neoplasm malignant (serious, 1 patient) Lung squamous cell carcinoma stage unspecified (serious, 1 patient) Multiple myeloma (serious, 1 patient) Prostate cancer metastatic (serious, 1 patient) Uterine leiomyoma (serious, 1 patient) Anterior spinal artery syndrome (serious, 1 patient) Burning sensation (serious, 1 patient) Cerebral haematoma (serious, 1 patient) Coma (serious, 1 patient) Diabetic neuropathy (serious, 1 patient) Dizziness (serious, 4 patients) Dysarthria (serious, 1 patient) Embolic stroke (serious, 2 patients) Epilepsy (serious, 2 patients) Haemorrhagic stroke (serious, 1 patient) Intracranial haematoma (serious, 1 patient) Loss of consciousness (serious, 1 patient) Metabolic encephalopathy (serious, 1 patient) Myasthenia gravis (serious, 1 patient) Myasthenia gravis crisis (serious, 1 patient) Neuropathy peripheral (serious, 1 patient) Somnolence (serious, 2 patients) Trigeminal neuralgia (serious, 1 patient) Unresponsive to stimuli (serious, 1 patient) Uraemic encephalopathy (serious, 1 patient) Abnormal behaviour (serious, 1 patient) Alcohol abuse (serious, 1 patient) Anxiety (serious, 1 patient) Confusional state (serious, 2 patients) Depression suicidal (serious, 1 patient) Screaming (serious, 1 patient) Bladder tamponade (serious, 1 patient) Haematuria (serious, 1 patient) Nephropathy (serious, 1 patient) Polyuria (serious, 1 patient) Renal artery stenosis (serious, 1 patient) Renal failure acute (serious, 20 patients) Renal impairment (serious, 5 patients) Benign prostatic hyperplasia (serious, 2 patients) Menorrhagia (serious, 1 patient) Acute pulmonary oedema (serious, 7 patients) Acute respiratory distress syndrome (serious, 1 patient) Acute respiratory failure (serious, 2 patients) Asthma (serious, 1 patient) Atelectasis (serious, 1 patient) Bronchiectasis (serious, 1 patient) Chronic obstructive pulmonary disease (serious, 13 patients) Dyspnoea (serious, 20 patients) Pneumonitis (serious, 1 patient) Pneumothorax (serious, 1 patient) Productive cough (serious, 1 patient) Pulmonary artery thrombosis (serious, 1 patient) Respiratory failure (serious, 6 patients) Wheezing (serious, 1 patient) Hyperhidrosis (serious, 2 patients) Skin ulcer (serious, 1 patient) Skin ulcer haemorrhage (serious, 1 patient) Extremity necrosis (serious, 1 patient) Hypotension (serious, 24 patients) Peripheral arterial occlusive disease (serious, 4 patients) Peripheral ischaemia (serious, 1 patient) Disorder peripheral vascular (serious, 2 patients) Phlebitis (serious, 1 patient) Diarrhoea (below serious, 49 patients) Hyperkalaemia (below serious, 155 patients) Renal impairment (below serious, 47 patients) Cough (below serious, 59 patients) Hypotension (below serious, 117 patients) |
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 25 Health Status: unhealthy Condition: Heart Failure and a Normal Ejection Fraction Population Size: 25 Sources: |
Other AEs: Thrush NOS... Other AEs: Thrush NOS (below serious, 1 patient) Sources: |
300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 34 Health Status: unhealthy Condition: Atherosclerosis Population Size: 34 Sources: |
Other AEs: Hyperkalemia... Other AEs: Hyperkalemia (below serious, 1 patient) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | 0.6% Disc. AE |
600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: Page: p.1161 |
unhealthy, 53 n = 166 Health Status: unhealthy Condition: Hypertension Age Group: 53 Sex: M+F Population Size: 166 Sources: Page: p.1161 |
Angioedema | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hypertension Sources: Page: p.1 |
Angioedema | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hypertension Sources: Page: p.1 |
Disorder fetal | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hypertension Sources: Page: p.1 |
Hyperkalemia | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hypertension Sources: Page: p.1 |
Hypotension | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hypertension Sources: Page: p.1 |
Impaired renal function | Disc. AE | 300 mg 1 times / day multiple, oral Recommended Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Hypertension Sources: Page: p.1 |
Lower extremities weakness of | below serious, 1 patient | 150 mg 1 times / day steady, oral Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: |
unhealthy n = 7 Health Status: unhealthy Condition: Kidney Transplant Population Size: 7 Sources: |
Diarrhea | below serious, 5 patients | 150 mg 1 times / day steady, oral Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: |
unhealthy n = 7 Health Status: unhealthy Condition: Kidney Transplant Population Size: 7 Sources: |
GI bleed | serious, 1 patient | 150 mg 1 times / day steady, oral Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: |
unhealthy n = 7 Health Status: unhealthy Condition: Kidney Transplant Population Size: 7 Sources: |
Knee hemarthrosis | serious, 1 patient | 150 mg 1 times / day steady, oral Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: |
unhealthy n = 7 Health Status: unhealthy Condition: Kidney Transplant Population Size: 7 Sources: |
Arthritis | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Asteroid hyalosis | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Choroidal neovascularisation | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Diarrhoea | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Epistaxis | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Fatigue | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Flatulence | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Foreign body sensation in eyes | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Fungal skin infection | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Hypoglycaemia | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Muscle spasms | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Myalgia | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Pain in extremity | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Pain in jaw | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Paraesthesia | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Respiratory tract infection | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Retinal neovascularisation | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Sinusitis | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Tooth fracture | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Vision blurred | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Vitreous detachment | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Basal cell carcinoma | below serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Hypotension | below serious, 2 patients | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Cellulitis | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Diabetic foot | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Pneumonia | serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 20 Health Status: unhealthy Condition: diabetic macular edema Population Size: 20 Sources: |
Hypotension | below serious, 117 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hyperkalaemia | below serious, 155 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Renal impairment | below serious, 47 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Diarrhoea | below serious, 49 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Cough | below serious, 59 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Abnormal behaviour | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Accidental overdose | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Acute respiratory distress syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Adenocarcinoma lung | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Alcohol abuse | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Anal abscess | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Ankle fracture | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Anterior spinal artery syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Anxiety | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Aortic valve incompetence | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Arteriospasm coronary | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Arthralgia | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Arthritis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Asthma | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Atelectasis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Bladder neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Bladder tamponade | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Bronchiectasis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Bronchitis bacterial | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Burning sensation | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Bursitis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Cardiomyopathy | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Cerebral haematoma | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Chest discomfort | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Colorectal cancer | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Coma | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Contusion | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Costochondritis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Decreased appetite | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Depression suicidal | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Dermatitis artefacta | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Device lead issue | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Diabetic ketoacidosis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Diabetic neuropathy | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Drug intolerance | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Duodenal ulcer haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Dysarthria | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Electric shock | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Enterocolitis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Extradural haematoma | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Extremity necrosis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Failure to thrive | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Femoral neck fracture | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Fibrosis myocardial | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Fluid intake reduced | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Gastritis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Gastrointestinal viral infection | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Haematuria | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Haemoglobin decreased | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Haemorrhagic disorder | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Haemorrhagic stroke | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Head injury | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Heart transplant rejection | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hepatic cirrhosis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hepatic cyst | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hepatic neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hepatitis B | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hepatobiliary neoplasm | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hepatorenal syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hiatus hernia | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hilar lymphadenopathy | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Infection localised | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Intestinal obstruction | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Intestinal polyp | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Intracranial haematoma | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Joint effusion | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Laceration | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Left ventricular dysfunction | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Liver abscess | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Loss of consciousness | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Low cardiac output syndrome | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Lung neoplasm malignant | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Lung squamous cell carcinoma stage unspecified | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Lymphadenopathy | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Menorrhagia | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Metabolic encephalopathy | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Multiple myeloma | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Muscular weakness | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Myasthenia gravis crisis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Myasthenia gravis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Necrosis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Nephropathy | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Neuropathy peripheral | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Orchitis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Osteomyelitis acute | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Paronychia | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Peripheral ischaemia | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Phlebitis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Pneumonitis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Pneumothorax | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Polyuria | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Post procedural haematoma | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Procedural haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Productive cough | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Prostate cancer metastatic | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Pubis fracture | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Pulmonary artery thrombosis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Renal artery stenosis | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Renal function test abnormal | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Retinal detachment | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Screaming | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Skin ulcer haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Skin ulcer | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Small intestinal obstruction | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Soft tissue inflammation | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Spinal compression fracture | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Splenic infarction | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Splenic rupture | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Tachyarrhythmia | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Thermal burn | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Trigeminal neuralgia | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Umbilical hernia, obstructive | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Unresponsive to stimuli | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Upper gastrointestinal haemorrhage | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Uraemic encephalopathy | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Uterine leiomyoma | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Ventricular extrasystoles | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Viral infection | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Wheezing | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Wound infection pseudomonas | serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Ventricular tachycardia | serious, 10 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Chronic obstructive pulmonary disease | serious, 13 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Acute respiratory failure | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Appendicitis | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Atrioventricular block complete | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Benign prostatic hyperplasia | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Cardiopulmonary failure | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Cholecystitis | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Colon cancer | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Confusional state | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Constipation | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Disorder peripheral vascular | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Embolic stroke | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Epilepsy | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Erysipelas | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Humerus fracture | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hyperhidrosis | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
International normalised ratio increased | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Pain in extremity | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Pseudomembranous colitis | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Somnolence | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Subdural haematoma | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Toxicity to various agents | serious, 2 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Dyspnoea | serious, 20 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Renal failure acute | serious, 20 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hypotension | serious, 24 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Atrial flutter | serious, 3 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Blood creatinine increased | serious, 3 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Cataract | serious, 3 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Lower respiratory tract infection | serious, 3 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Respiratory tract infection | serious, 3 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Tachycardia | serious, 3 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Coronary artery disease | serious, 4 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Dizziness | serious, 4 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Femur fracture | serious, 4 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Peripheral arterial occlusive disease | serious, 4 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Vertigo | serious, 4 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Renal impairment | serious, 5 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Vomiting | serious, 5 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Anaemia | serious, 6 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Chest pain | serious, 6 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Respiratory failure | serious, 6 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Acute pulmonary oedema | serious, 7 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Angina unstable | serious, 7 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Cardio-respiratory arrest | serious, 7 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Cardiogenic shock | serious, 7 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Hypoglycaemia | serious, 7 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Non-cardiac chest pain | serious, 7 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Nausea | serious, 8 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Sepsis | serious, 8 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Sudden death | serious, 9 patients | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 808 Health Status: unhealthy Condition: acute decompensated Heart Failure Population Size: 808 Sources: |
Thrush NOS | below serious, 1 patient | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 25 Health Status: unhealthy Condition: Heart Failure and a Normal Ejection Fraction Population Size: 25 Sources: |
Hyperkalemia | below serious, 1 patient | 300 mg 1 times / day steady, oral (max) Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy n = 34 Health Status: unhealthy Condition: Atherosclerosis Population Size: 34 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 12.0 |
no [Inhibition 100 uM] | |||
Page: 12.0 |
no [Inhibition 100 uM] | |||
Page: 12.0 |
no [Inhibition 100 uM] | |||
Page: 12.0 |
no [Inhibition 100 uM] | |||
Page: 46.0 |
no [Inhibition 200 uM] | |||
Page: 46.0 |
no [Inhibition 200 uM] | |||
Page: 46.0 |
no [Inhibition 200 uM] | |||
Page: 47.0 |
no | |||
Page: 21.0 |
no | |||
Page: 30.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 30, 57 |
inconclusive | |||
Page: 30.0 |
major | yes (co-administration study) Comment: itraconazole increased Cmax by 5-fold and AUC by 6-fold; ketaconazole increased Cmax a nd AUC by 2-fold; cyclosporine increased Cmax by 5-fold and AUC by 3-fold Page: 30.0 |
||
Page: 30, 55, 56 |
minor | |||
Page: 31.0 |
no | |||
Page: 31.0 |
no | |||
Page: 31, 57 |
no | |||
Page: 31, 57 |
no | |||
Page: 31.0 |
yes | yes (co-administration study) Comment: from clinical pharmacology review pdf 4: ketaconazole increased Cmax by 81% and AUC by 76%; from product label: itraconazole increased Cmax by 5-fold and AUC by 6-fold; cyclosporine increased Cmax by 5-fold and AUC by 3-fold Page: 31.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 46, 69 |
PubMed
Title | Date | PubMed |
---|---|---|
Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. | 2006 Dec |
|
Direct renin inhibition with aliskiren in hypertension and target organ damage. | 2006 Mar |
|
Aliskiren: a review of its use in the management of hypertension. | 2007 |
|
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. | 2007 |
|
Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. | 2007 |
|
The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. | 2007 |
|
Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement. | 2007 |
|
[Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?]. | 2007 Apr |
|
Gateways to clinical trials. | 2007 Apr |
|
Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. | 2007 Apr |
|
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? | 2007 Apr |
|
Aliskiren (Tekturna) for hypertension. | 2007 Apr 9 |
|
Antihypertensive therapies. | 2007 Aug |
|
Novel drugs targeting hypertension: renin inhibitors. | 2007 Aug |
|
Renin inhibition: a new modality for hypertension management. | 2007 Aug |
|
Direct renin inhibitors: a new approach to antihypertensive drug treatment. | 2007 Aug |
|
Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition. | 2007 Aug |
|
Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. | 2007 Aug |
|
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. | 2007 Aug 2 |
|
Mechanisms of progression of chronic kidney disease. | 2007 Dec |
|
[Global treatment of cardiovascular risk in the hypertensive patient]. | 2007 Feb |
|
[The best of clinical pharmacology in 2006]. | 2007 Jan |
|
[The best of hypertension in 2006]. | 2007 Jan |
|
Aliskiren (Tekturna) a new weapon to battle the silent killer. | 2007 Jul |
|
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. | 2007 Jul 21 |
|
Dual inhibition of the renin system by aliskiren and valsartan. | 2007 Jul 21 |
|
Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. | 2007 Jun |
|
A brief response to Sealey and Laragh. | 2007 Jun |
|
A new weapon against hypertension. Recently approved medication lowers blood pressure, reducing risks of heart failure, stroke, heart attack, aneurysm, and kidney failure. | 2007 Jun |
|
Gateways to clinical trials. | 2007 Mar |
|
Aliskiren for renin inhibition: a new class of antihypertensives. | 2007 Mar |
|
Do we need yet another blocker of the renin-angiotensin system? | 2007 Mar 20 |
|
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. | 2007 Mar 20 |
|
Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. | 2007 Mar 22 |
|
A new way to control blood pressure. Inactivating renin, which is made by the kidneys, may open the door to better blood pressure. | 2007 May |
|
Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. | 2007 May |
|
What new drugs can nephrologists look forward to in the next year or two? | 2007 May |
|
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. | 2007 May |
|
New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib. | 2007 May-Jun |
|
Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. | 2007 Nov |
|
A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. | 2007 Oct |
|
Renin inhibition: the holy grail of renin-angiotensin system blockade? | 2007 Oct |
|
Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets. | 2007 Oct 4 |
|
Aliskiren, the future of renin-angiotensin system blockade? | 2007 Sep |
|
The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. | 2007 Sep |
|
Inhibition of renin: an updated review of the development of renin inhibitors. | 2007 Sep |
|
Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. | 2007 Sep |
|
Renin excess after renin inhibition: malefactor or innocent bystander? | 2007 Sep |
|
Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. | 2007 Sep |
|
Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. | 2007 Sep-Oct |
Sample Use Guides
Starting dose: 150 mg once daily with a routine pattern with regard
to meals. If blood pressure remains uncontrolled titrate up to
300 mg daily (2.1, 2.3)
Majority of effect of given dose attained in 2 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27062013
Aliskiren (0.1 or 10 uM) dose-dependently improved functions and increased both VEGF and stromal cell-derived factor-1α (SDF-1α) expression of EPCs from patients with T2DM or EPCs from healthy volunteers and treated with high glucose.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175900
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
WHO-VATC |
QC09XA02
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
WHO-VATC |
QC09XA53
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
WHO-ATC |
C09XA53
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
WHO-ATC |
C09XA54
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
WHO-ATC |
C09XA02
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
WHO-ATC |
C09XA52
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
NDF-RT |
N0000175899
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
WHO-ATC |
C09DX02
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
WHO-VATC |
QC09XA52
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
LIVERTOX |
NBK548884
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
||
|
WHO-VATC |
QC09DX02
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ALISKIREN
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
7843
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
m1509
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
173334-57-1
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
502FWN4Q32
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
DTXSID40891494
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL1639
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
325646
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
502FWN4Q32
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
C65222
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
119
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
C446481
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
601027
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
7992
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
RR-38
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
4812
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
100000089565
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
5493444
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
SUB21380
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY | |||
|
DB09026
Created by
admin on Sat Dec 16 16:41:21 GMT 2023 , Edited by admin on Sat Dec 16 16:41:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)